News & Updates

Show Multimedia Only

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

Treatment with cilofexor in patients with noncirrhotic primary sclerosing cholangitis (PSC) does not appear to reduce the rate of fibrosis progression, according to a phase III study.

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

4 hours ago

Vedolizumab better used in early- vs late-stage Crohn’s disease

16 hours ago

In patients with Crohn’s disease (CD), initiating treatment with vedolizumab early than late in the disease course may lead to better safety and efficacy outcomes, according to a phase IV open-label cohort study.

Vedolizumab better used in early- vs late-stage Crohn’s disease

16 hours ago

Bridging the gap: Enhancing preventive care in high-risk populations

20 hours ago

A recent symposium held in conjunction with the 19th Singapore Public Health and Occupational Medicine Conference convened three experts: Dr Behram Ali Khan, Senior Consultant Nephrologist and Assistant Professor of Medicine, Renal Health Services; Dr Aziz Noordin, Family Physician, Tampines Family Medicine Clinic; and Dr Wee Xue Ting, Cardiology Specialist Pharmacist, iRx Clinical Pharmacy, to examine persistent gaps in preventive care for high-risk populations and discuss practical, scalable solutions. Against a backdrop of rising chronic disease burden, decreasing vaccination uptake, and continued vulnerability among medically complex patients, this symposium highlighted the vital role primary care teams play in modifying risk, improving early detection, and strengthening trust in preventive interventions.

Bridging the gap: Enhancing preventive care in high-risk populations

20 hours ago

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

20 hours ago

Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

20 hours ago

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

20 hours ago

Prescribing patterns for nirmatrelvir/ritonavir within a healthcare system in Eastern Massachusetts, US, reveal significant demographic and socioeconomic differences, according to a retrospective study.

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

20 hours ago

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

20 hours ago

A study presented at IDWeek 2025 demonstrates substantial medication cost savings, shorter hospital stays, reduced treatment duration, and lower rates of progression to severe disease when nirmatrelvir-ritonavir (NMV/r) was added to the acute care formulary for treating elderly patients with mild-to-moderate COVID-19.

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

20 hours ago

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

20 hours ago

Treatment with nirmatrelvir/ritonavir (NMV/r) provides good value for money because of its health benefits for patients with mild-to-moderate COVID-19 who are at an increased risk of progressing to severe disease, according to the results of a systematic literature review of economic value.

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

20 hours ago

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

20 hours ago

Treatment with nirmatrelvir/ritonavir significantly reduced mortality risk among hospitalized COVID-19 patients compared with the combined molnupiravir and nirmatrelvir/ritonavir regimen, according to a target trial emulation study presented at IDWeek 2025.

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

20 hours ago

Reduced symptom burden, faster recovery with NMV/r vs placebo

20 hours ago

Treatment with nirmatrelvir/ritonavir (NMV/r) reduced both the duration and severity of COVID-19 symptoms, based on patients’ overall perception of their symptom burden, and facilitated a faster return to normal health and activities, as demonstrated in a recent exploratory analysis.

Reduced symptom burden, faster recovery with NMV/r vs placebo

20 hours ago

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

22 hours ago by

The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

22 hours ago

News & Updates

Filter by Specialty:

Specialty:

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

Vedolizumab better used in early- vs late-stage Crohn’s disease

Vedolizumab better used in early- vs late-stage Crohn’s disease

Bridging the gap: Enhancing preventive care in high-risk populations

Bridging the gap: Enhancing preventive care in high-risk populations

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Reduced symptom burden, faster recovery with NMV/r vs placebo

Reduced symptom burden, faster recovery with NMV/r vs placebo

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI